These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 15657365)
1. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. Ifergan I; Jansen G; Assaraf YG Mol Pharmacol; 2005 Apr; 67(4):1349-59. PubMed ID: 15657365 [TBL] [Abstract][Full Text] [Related]
2. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. Ifergan I; Shafran A; Jansen G; Hooijberg JH; Scheffer GL; Assaraf YG J Biol Chem; 2004 Jun; 279(24):25527-34. PubMed ID: 15047700 [TBL] [Abstract][Full Text] [Related]
4. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Assaraf YG Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765 [TBL] [Abstract][Full Text] [Related]
5. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Rhee MS; Schneider E Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721 [TBL] [Abstract][Full Text] [Related]
6. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Lemos C; Kathmann I; Giovannetti E; Beliën JA; Scheffer GL; Calhau C; Jansen G; Peters GJ Mol Cancer Ther; 2009 Mar; 8(3):655-64. PubMed ID: 19240161 [TBL] [Abstract][Full Text] [Related]
7. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Breedveld P; Pluim D; Cipriani G; Dahlhaus F; van Eijndhoven MA; de Wolf CJ; Kuil A; Beijnen JH; Scheffer GL; Jansen G; Borst P; Schellens JH Mol Pharmacol; 2007 Jan; 71(1):240-9. PubMed ID: 17032904 [TBL] [Abstract][Full Text] [Related]
8. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase. Ji N; Yuan J; Liu J; Tian S Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767 [TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Hooijberg JH; de Vries NA; Kaspers GJ; Pieters R; Jansen G; Peters GJ Cancer Chemother Pharmacol; 2006 Jul; 58(1):1-12. PubMed ID: 16362298 [TBL] [Abstract][Full Text] [Related]
10. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043 [TBL] [Abstract][Full Text] [Related]
11. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Mohrmann K; van Eijndhoven MA; Schinkel AH; Schellens JH Cancer Chemother Pharmacol; 2005 Oct; 56(4):344-50. PubMed ID: 15875186 [TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Doyle L; Ross DD Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842 [TBL] [Abstract][Full Text] [Related]
14. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629 [TBL] [Abstract][Full Text] [Related]
15. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells]. Zhang YH; Li G; Yu J; Xu MS; Liu ZX Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044 [TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Shepard RL; Cao J; Starling JJ; Dantzig AH Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064 [TBL] [Abstract][Full Text] [Related]
17. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells. Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of adaptation to folate deficiency. Ifergan I; Assaraf YG Vitam Horm; 2008; 79():99-143. PubMed ID: 18804693 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]